Denali Announce Positive LRRK2 Trial Results with Advance to Phase 1b Trial

Denali Announce Positive LRRK2 Trial Results with Advance to Phase 1b Trial
Denali Therapeutics has announced positive clinical results from their LRRK2 inhibitor programme and their advance to a Phase 1b trial in Parkinson’s patients with and without a genetic LRRK2 mutation. Genetic mutations (or variants) within the LRRK2 gene are recognised as being some of the most common with regards to increasing ones risk of developing Parkinson’s. But despite being one ... read more
Source: Published on 2018-08-16